Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

Overview

Journal Kidney Dis (Basel)

Specialty Nephrology

Date 2017 Aug 9

PMID 28785559

Citations 4

Authors

Berthold Hocher

Andreas Pasch

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients.

Summary: In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified.

Key Message: There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome.

Citing Articles

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients.

Zuo J, Hasan A, Hocher C, Kalk P, Kleuser B, Kramer B Front Endocrinol (Lausanne). 2023; 14:1178166.

PMID: 37324252 PMC: 10264784. DOI: 10.3389/fendo.2023.1178166.

Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis.

Liu B, Chong F, Yuan C, Liu Y, Yang H, Wang W Front Pharmacol. 2021; 11:586725.

PMID: 33708111 PMC: 7941278. DOI: 10.3389/fphar.2020.586725.

Association of Vitamin D and Parathyroid Hormone with Insulin Sensitivity, Beta Cell Function and Gestational Diabetes in Pregnancy: A Cross-Sectional, Observational Study.

Nachankar A, Kotwal N, Upreti V, Verma V, Hari Kumar K Diabetes Ther. 2018; 9(5):2081-2090.

PMID: 30206904 PMC: 6167303. DOI: 10.1007/s13300-018-0508-z.

Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.

Lang F, Leibrock C, Pelzl L, Gawaz M, Pieske B, Alesutan I Front Endocrinol (Lausanne). 2018; 9:207.

PMID: 29780355 PMC: 5945862. DOI: 10.3389/fendo.2018.00207.

References

Blacher J, Guerin A, Pannier B, Marchais S, London G . Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38(4):938-42. DOI: 10.1161/hy1001.096358. View

Chu L, Forte L, Anast C, Cohn D . Interaction of parathyroid hormone with membranes of kidney cortex: degradation of the hormone and activation of adenylate cyclase. Endocrinology. 1975; 97(4):1014-23. DOI: 10.1210/endo-97-4-1014. View

Himmelfarb J, Stenvinkel P, Ikizler T, Hakim R . The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62(5):1524-38. DOI: 10.1046/j.1523-1755.2002.00600.x. View

Hocher B, Ziebig R, Krause R, Asmus G, Neumayer H, Liefeldt L . Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation. 2004; 109(19):2266-8. DOI: 10.1161/01.CIR.0000128598.72920.B5. View

Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter C . Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens. 2005; 23(5):1067-75. DOI: 10.1097/01.hjh.0000166849.72721.1c. View

Pang P, Wang R, Shan J, Karpinski E, Benishin C . Specific inhibition of long-lasting, L-type calcium channels by synthetic parathyroid hormone. Proc Natl Acad Sci U S A. 1990; 87(2):623-7. PMC: 53317. DOI: 10.1073/pnas.87.2.623. View

Hocher B, Liefeldt L, Quaschning T, Kalk P, Ziebig R, Godes M . Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol. 2007; 18(4):1323-30. DOI: 10.1681/ASN.2006070684. View

McIntosh C, Hesch R . Characterization of the parathyrin receptor in renal plasma membranes by labelled hormone and labelled antibody binding techniques. Biochim Biophys Acta. 1976; 426(3):535-46. DOI: 10.1016/0005-2736(76)90397-7. View

Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A . Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2010; 26(6):1948-55. PMC: 3107766. DOI: 10.1093/ndt/gfq219. View

10.

Martin K, Freitag J, Conrades M, Hruska K, KLAHR S, Slatopolsky E . Selective uptake of the synthetic amino terminal fragment of bovine parathyroid hormone by isolated perfused bone. J Clin Invest. 1978; 62(2):256-61. PMC: 371761. DOI: 10.1172/JCI109124. View

11.

Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E . Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010; 21(11):1998-2007. PMC: 3014014. DOI: 10.1681/ASN.2009090944. View

12.

Zebger-Gong H, Muller D, Diercke M, Haffner D, Hocher B, Verberckmoes S . 1,25-Dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. J Hypertens. 2010; 29(2):339-48. DOI: 10.1097/HJH.0b013e328340aa30. View

13.

Lopez I, Rodriguez-Ortiz M, Almaden Y, Guerrero F, Montes de Oca A, Pineda C . Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011; 80(5):475-82. DOI: 10.1038/ki.2011.107. View

14.

Chaykovska L, Tsuprykov O, Hocher B . Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab. 2011; 57(7-8):455-67. View

15.

Moorthi R, Moe S . CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011; 58(6):1022-36. PMC: 3983665. DOI: 10.1053/j.ajkd.2011.08.009. View

16.

Freitag J, Martin K, Conrades M, Slatopolsky E . Metabolism of parathyroid hormone by fetal rat calvaria. Endocrinology. 1979; 104(2):510-6. DOI: 10.1210/endo-104-2-510. View

17.

Hocher B, Armbruster F, Stoeva S, Reichetzeder C, Gron H, Lieker I . Measuring parathyroid hormone (PTH) in patients with oxidative stress--do we need a fourth generation parathyroid hormone assay?. PLoS One. 2012; 7(7):e40242. PMC: 3391306. DOI: 10.1371/journal.pone.0040242. View

18.

Pasch A, Farese S, Graber S, Wald J, Richtering W, Floege J . Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol. 2012; 23(10):1744-52. PMC: 3458464. DOI: 10.1681/ASN.2012030240. View

19.

Chertow G, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W . Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367(26):2482-94. DOI: 10.1056/NEJMoa1205624. View

20.

Fouque D, Roth H, Pelletier S, London G, Hannedouche T, Jean G . Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?. Nephrol Dial Transplant. 2012; 28(2):360-7. DOI: 10.1093/ndt/gfs404. View